Iowanews Headlines

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market to Grow at USD 5.8 Billion by 2025 | Worldwide Analysis Report by Treatment, 2018 to 2025

 Breaking News
  • No posts were found

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market to Grow at USD 5.8 Billion by 2025 | Worldwide Analysis Report by Treatment, 2018 to 2025

August 05
23:46 2019
Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market to Grow at USD 5.8 Billion by 2025 | Worldwide Analysis Report by Treatment, 2018 to 2025

Grand View Research, Inc. – Market Research And Consulting.
According to report published by Grand View Research, The global paroxysmal nocturnal hemoglobinuria (PNH) treatment market size was valued at USD 2.24 billion in 2017. It is expected to exhibit a CAGR of 11.2% during the forecast period

The global paroxysmal nocturnal hemoglobinuria (PNH) treatment market size is expected to reach USD 5.8 billion by 2025 at an 11.2% CAGR during the forecast period, according to a new report by Grand View Research, Inc. Several factors such as rise in number of blood and bone marrow related disorders, increase in geriatric population, wider adoption of novel therapeutics, and emergence of biologics are driving the market.

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, chronic hematologic disorder. It is an ultra-rare disease with approximately 8,000 to 10,000 cases reported in North America and Europe. The life-threatening disease often manifests in three forms: thrombosis, persistent intravascular hemolysis, and pancytopenia. Although information on its prevalence is scarce, PNH is estimated to affect more than 20,000 people worldwide with an incidence of about 1.3 per million annually and a prevalence of around 16 per million. PNH affects men and women equally. Although physical symptoms can begin at any age, they usually develop between 30-40 years of age.

Request a Sample Copy of the Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Research Report @ https://www.grandviewresearch.com/industry-analysis/paroxysmal-nocturnal-hemoglobinuria-pnh-market/request/rs1

Novel treatments including monoclonal antibodies, recombinant proteins, and cyclic peptides are gaining penetration in developed markets. However, high cost of therapy with Soliris and other emerging pipeline drugs presents a barrier in adoption in developing regions. Blood transfusion and supportive care are anticipated to lose momentum during the forecast period due to adverse side effects and sub-optimal efficacy.

U.S. PNH treatment market size, by treatment type, 2017 - 2025 (USD Million)

Further key findings from the study suggest: 

  • An estimated 5,000 – 6,000 people in U.S. suffer from PNH, with approximately 450 new cases being reported annually
  • U.S. dominated the global PNH treatment market with more than 35% share in 2017 due to high cost of treatment in U.S., potential approval of a range of pipeline drugs, and adoption of novel therapeutics
  • Treatment with medication dominated the PNH market with a share of more than 75% in 2017. Apart from drugs, the stem cell transplant segment is projected to witness double-digit growth through the forecast period
  • Alexion, Akari, Apellis, Amgen, CinnaGen, Ra Pharmaceuticals, Alnylam, Achillion, Novartis, Roche, and Regeneron Pharmaceuticals are some of the key players in this market
  • Currently, 16 products are under clinical evaluation for PNH treatment in various stages of development. Promising pipeline candidates such as ALXN1210, Coversin, APL2, and RA101495 offer significant commercial potential post regulatory approval.

Global PNH treatment market share, by country, 2017 (%)

Have Any Query? Ask Our Experts @ https://www.grandviewresearch.com/inquiry/5393/ibb

Grand View Research has segmented the global paroxysmal nocturnal hemoglobinuria (PNH) treatment market based on treatment and major markets:

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Outlook (Revenue, USD Million; 2017 – 2025)

  • Medication
  • Stem Cell Transplant
  • Blood Transfusion

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Country Outlook (Revenue, USD Million, 2017 – 2025)

  • U.S.
  • Japan
  • U.K.
  • Germany
  • France
  • Spain
  • Italy

Browse Related Report:

Cold Plasma Market: https://www.grandviewresearch.com/industry-analysis/cold-plasma-market

Pharmaceutical Grade Lactose Market: https://www.grandviewresearch.com/industry-analysis/pharmaceutical-grade-lactose-market

About Grand View Research

Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.

Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:201, Spear Street, 1100
City: San Francisco
State: California
Country: United States
Website: www.grandviewresearch.com/press-release/global-paroxysmal-nocturnal-hemoglobinuria-pnh-treatment-market